Literature DB >> 9119156

Virus removal studies using nanofiltration membranes.

J O'Grady1, A Losikoff, J Poiley, D Fickett, C Oliver.   

Abstract

Nanofiltration of immunoglobulin products was investigated as a virus removal step using Planova-controlled pore size membranes. For these studies, purified preparations of an IgG and an IgM were tested with 15 nm and 35 nm Planovace nanofiltration membranes, respectively. The results of spiking studies with four model viruses indicated that both the Planova 15 and 35 membranes removed 6-7 log10 plaque or focus forming units of murine xenotropic retrovirus, simian virus 40 and pseudorabies virus. Although two tandem Planova 35 membranes were tested for clearance of poliovirus, only the Planova 15 membrane removed this virus. Nanofiltration experiments were carried out with protein concentrations up to 12 mg/ml for the IgG and 1-2 mg/ml for the IgM, and protein recovery was excellent.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9119156

Source DB:  PubMed          Journal:  Dev Biol Stand        ISSN: 0301-5149


  5 in total

1.  Efficacy, pharmacokinetics, safety, and tolerability of Flebogamma 10% DIF, a high-purity human intravenous immunoglobulin, in primary immunodeficiency.

Authors:  Melvin Berger; Paul J Pinciaro; Arthur Althaus; Mark Ballow; Akhilesh Chouksey; James Moy; Hans Ochs; Mark Stein
Journal:  J Clin Immunol       Date:  2009-12-08       Impact factor: 8.317

Review 2.  Virus safety of intravenous immunoglobulin: future challenges.

Authors:  Nicola Boschetti; Martin Stucki; Peter J Späth; Christoph Kempf
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

3.  Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins.

Authors:  Christoph Kempf; Martin Stucki; Nicola Boschetti
Journal:  Biologicals       Date:  2006-04-03       Impact factor: 1.856

Review 4.  Intravenous immunoglobulins: evolution of commercial IVIG preparations.

Authors:  John A Hooper
Journal:  Immunol Allergy Clin North Am       Date:  2008-11       Impact factor: 3.479

5.  Nanofiltration as a robust method contributing to viral safety of plasma-derived therapeutics: 20 years' experience of the plasma protein manufacturers.

Authors:  Nathan J Roth; Herbert O Dichtelmüller; Fabrizio Fabbrizzi; Eckhard Flechsig; Albrecht Gröner; Mary Gustafson; Juan I Jorquera; Thomas R Kreil; Dominika Misztela; Elisa Moretti; Mila Moscardini; Gerhard Poelsler; John More; Peter Roberts; Andreas Wieser; Rodrigo Gajardo
Journal:  Transfusion       Date:  2020-08-19       Impact factor: 3.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.